Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. 1978

H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis

Fifty chronic schizophrenics were randomly assigned to a 16-week treatment either with fluspirilene or with fluphenazine decanoate. The aim of the study was to compare the antipsychotic action and the side effects of the two neuroleptics. Fluphenazine decanoate caused more side effects and the difference between the two groups was statistically significant in the items tremor, severe extrapyramidal effects and parkinsonism. More patients in the fluspirilene group (nine patients) compared with only three in the fluphenazine decanoate group remained free of side effects during the whole trial. Judged from the BPRS fluspirilene proved an equally potent neuroleptic with fluphenazine decanoate although statistically significant improvement has been obtained in more items of the scale in the fluspirilene group. The improvement in the NOSIE-30 was much more clear in the fluspirilene group. Although Clinical Global Impressions of the investigators and the nursing personnel favored fluspirilene, the differences between the two groups were not statistically significant.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine
D005484 Fluspirilene A long-acting injectable antipsychotic agent used for chronic schizophrenia. Spirodiflamine,Fluspi,Fluspirilen Beta,Fluspirilen Lindo,Imap,Kivat,Redeptin,Beta, Fluspirilen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
November 1982, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
October 1973, The British journal of clinical practice,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
September 1970, Diseases of the nervous system,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
September 1972, Lancet (London, England),
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
October 1979, Acta psychiatrica Scandinavica,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
June 1983, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
August 1976, Current therapeutic research, clinical and experimental,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
May 1982, The Journal of clinical psychiatry,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
December 1994, The American journal of psychiatry,
H Frangos, and N P Zissis, and I Leontopoulos, and N Diamantas, and S Tsitouridis, and I Gavriil, and K Tsolis
April 1976, Psychopharmacology bulletin,
Copied contents to your clipboard!